• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
Alzheimer's Clinical Trials Consortium

Alzheimer's Clinical Trials Consortium

  • Submit a Proposal
  • About Us
    • Committees
    • Units
  • Projects
  • Sites
  • News
  • Alzheimer’s Information
  • Contact Us

Biostatistics

Rema Raman, PhD

September 26, 2019 by

Rema Raman, PhD, is a tenured Professor of Neurology at the Keck School of Medicine of the University of Southern California (USC), the Director of Biostatistics of USC’s Alzheimer’s Therapeutic Research Institute (ATRI), and the Director of the Biostatistics Unit for the Alzheimer’s Clinical Trials Consortium (ACTC).   Dr. Raman also serves as Co-Lead for the ACTC Recruitment, Engagement, and Retention Unit and Co-Chair of the Inclusion, Diversity and Education in Alzheimer’s disease – Clinical Trials (IDEA-CT) Unit. She is also Co-Chair of the Project Feasibility Committee. Dr. Raman received her training in biostatistics from the School of Public Health at the University of Illinois at Chicago. Her statistical research interests are in efficient clinical trial design and monitoring approaches (risk-based monitoring, data visualization), and correlated data analysis topics (impact of missing data, analysis of ordinal data). Dr. Raman has extensive experience as a biostatistician in biomedical research projects, providing biostatistics and data management leadership to the design, coordination, conduct and analyses of clinical trials and large observational studies. She has served or currently serves as the primary statistician for several, multi-center clinical trials in Alzheimer’s disease, acute stroke, post-traumatic stress disorder, and traumatic brain injury. She is a regular member of the NIH CNN study section, an ad-hoc member on several others and serves as the Biostatistician on several Data and Safety Monitoring Boards.

Michael Donohue, PhD

September 20, 2019 by

Dr. Donohue co-leads the Biostatistics Unit. His primary interests include modeling the long-term, multivariate evolution of Alzheimer’s Disease, and utilizing these models to inform ACTC clinical trial design. Dr. Donohue guides the unit on the use of analytic power calculations and model-based simulations to drive clinical trial design decisions regarding sample size, duration, analysis approach, and outcome measures. He helps ensure that ACTC trials are conducted with maximum statistical power and minimum participant burden. He helped develop the first Preclinical Alzheimer’s trials, and the Preclinical Alzheimer’s Cognitive Composite (PACC). Research funded by his R01 lead to a novel hierarchical Bayesian model, the Latent Time Joint Mixed-Effects Model (LTJMM). The model can simultaneously estimate long-term trajectories of several disease markers and includes a subject-specific latent time shift parameter to account for heterogeneity in disease stage.

Primary Sidebar

Recent Comments

    Archives

      Categories

      • No categories

      Meta

      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org

      Categories

      • No categories

      Footer

      Alzheimer's Clinical Trials Consortium
      Alzheimer's Clinical Trials Consortium

      ACTC is funded by a Cooperative Agreement from the National Institute on Aging, National Institutes of Health.  Cooperative Agreement number U24AG057437.

      • Submit a Proposal
      • About Us
      • Projects
      • Sites
      • Job Opportunities
      • News
      • Alzheimer’s Information
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • California Privacy Rights
      ACTC Member ResourcesSubmit A Proposal

      Copyright © USC ATRI 2023. All Rights Reserved.